Global Degenerative Disc Disease Clinical Trials 2025: Drug Pipeline, Regulatory Approvals, and Market Growth Analysis by DelveInsight

DelveInsight's "Degenerative Disc Disease Pipeline Insight, 2025" report delivers an extensive analysis of the current clinical development landscape and future growth opportunities in the Degenerative Disc Disease market.

According to DelveInsight's evaluation, the global Degenerative Disc Disease pipeline features over 15 key companies engaged in developing more than 15 drugs. The report examines ongoing clinical trials, therapeutic approaches, mechanisms of action (MOA), routes of administration (ROA), and the latest advancements in the field.

Covering products from the pre-clinical stage through to marketed therapies, the report provides a thorough commercial and clinical review. It includes detailed drug profiles outlining mechanisms of action, clinical trial data, NDA approval status, and product development updates, along with insights into associated technologies, partnerships, mergers and acquisitions, funding activities, regulatory designations, and other relevant product-related developments.

Download sample report to know more in detail about emerging therapies @ https://www.delveinsight.com/sample-request/degenerative-disc-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Some of the key takeaways from the Degenerative Disc Disease Pipeline Report:
• Degenerative Disc Disease Companies across the globe are diligently working toward developing novel Degenerative Disc Disease treatment therapies with a considerable amount of success over the years.
• Degenerative Disc Disease companies working in the treatment market are Spine BioPharma, Inc., BioRestorative Therapies, Mesoblast, Ltd., Biosplice Therapeutics, Causeway Therapeutics, AnGes, Inc., DiscGenics, Kuros Biosciences, BioRestorative Therapies, Angitia Biopharmaceuticals, and others, are developing therapies for the Degenerative Disc Disease treatment
• Emerging Degenerative Disc Disease therapies in the different phases of clinical trials are- SB-01, BRTX-100, Rexlemestrocel-L, Lorecivivint, CWT 002, AMG0103, IDCT, KUR 113, BRTX-100, AGA111, and others are expected to have a significant impact on the Degenerative Disc Disease market in the coming years.
• In April 2025, DiscGenics, Inc., a privately owned, late-stage clinical biopharmaceutical company focused on developing allogeneic, cell-based regenerative therapies for musculoskeletal conditions, announced that its double-blind, peer-reviewed study titled "Allogeneic Disc Progenitor Cells Safely Increase Disc Volume and Improve Pain, Disability, and Quality of Life in Patients With Lumbar Disc Degeneration-Results of an FDA-Approved Biologic Therapy Randomized Clinical Trial," has been recognized as one of the top three most impactful articles published in the International Journal of Spine Surgery (IJSS) in 2024.
• In March 2025, Discure Technologies, a clinical-stage medical device company focused on innovative solutions for degenerative disc disease and other orthopedic conditions, announced its acceptance into the U.S. Food and Drug Administration's (FDA) Total Product Life Cycle (TPLC) Advisory Program (TAP). This inclusion is expected to accelerate patient access to the company's bioelectronic implant, the Discure System, which was previously granted Breakthrough Device designation by the FDA.
• In September 2024, Spine BioPharma Inc.-a company developing non opioid, non surgical therapies for degenerative disc disease-has finished enrolling patients in its U.S. Phase 3 trial of SB 01 for Injection. The MODEL study (MOderate-Severe Degenerative Disc Disease Evaluation of the Lumbar Spine) recruited 417 participants over two years at 30 research centers nationwide. SB 01 is the first intradiscal drug therapy to advance to Phase 3 testing for chronic low back pain and associated functional loss caused by degenerative disc disease.

Degenerative Disc Disease Overview
Degenerative Disc Disease is a spinal condition involving the gradual breakdown of the intervertebral discs that serve as shock absorbers between the vertebrae. This degeneration commonly occurs as part of the natural aging process but may also result from injury, repetitive stress, or genetic factors. Over time, the discs lose hydration, elasticity, and height, reducing their ability to cushion the spine and sometimes leading to disc herniation or spinal instability.

Degenerative Disc Disease can affect any region of the spine but is most frequently seen in the cervical (neck) and lumbar (lower back) areas. Symptoms can range from mild discomfort to severe, persistent pain, stiffness, and restricted movement. In some cases, nerve compression can cause pain, numbness, or weakness radiating into the arms or legs. Risk factors include aging, smoking, obesity, poor posture, and occupations involving heavy physical work.

Diagnosis typically involves a combination of medical history, physical examination, and imaging studies such as X-rays, MRI, or CT scans. While there is no cure to reverse Degenerative Disc Disease, treatment focuses on pain management and functional improvement through physical therapy, medications, and lifestyle changes. In advanced cases, surgical interventions like spinal fusion or artificial disc replacement may be recommended.

Get a Free Sample PDF Report to know more about Degenerative Disc Disease Pipeline Therapeutic Assessment - https://www.delveinsight.com/report-store/degenerative-disc-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Emerging Degenerative Disc Disease Drugs Under Different Phases of Clinical Development Include:
• SB-01: Spine BioPharma, Inc.
• BRTX-100: BioRestorative Therapies
• Rexlemestrocel-L: Mesoblast, Ltd.
• Lorecivivint: Biosplice Therapeutics
• CWT 002: Causeway Therapeutics
• AMG0103: AnGes, Inc.
• IDCT: DiscGenics
• KUR 113: Kuros Biosciences
• BRTX-100: BioRestorative Therapies
• AGA111: Angitia Biopharmaceuticals

Degenerative Disc Disease Route of Administration
Degenerative Disc Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Degenerative Disc Disease Molecule Type
Degenerative Disc Disease Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Degenerative Disc Disease Pipeline Therapeutics Assessment
• Degenerative Disc Disease Assessment by Product Type
• Degenerative Disc Disease By Stage and Product Type
• Degenerative Disc Disease Assessment by Route of Administration
• Degenerative Disc Disease By Stage and Route of Administration
• Degenerative Disc Disease Assessment by Molecule Type
• Degenerative Disc Disease by Stage and Molecule Type

DelveInsight's Degenerative Disc Disease Report covers around 15+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

The report offers detailed insights into Degenerative Disc Disease products in development. Access the full Degenerative Disc Disease pipeline report to explore emerging therapies and advancements: https://www.delveinsight.com/sample-request/degenerative-disc-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Several leading companies are actively advancing therapies in the Degenerative Disc Disease therapeutics market. Key players include Mesoblast Ltd., BioRestorative Therapies, DiscGenics Inc., Biosplice Therapeutics, Boehringer Ingelheim, SpineOvations, BIOPHARM GmbH, Yuhan, Histogen Inc., Spine BioPharma Inc., Angitia Biopharmaceuticals, Notogen, AnGes Inc., FibroGenesis, Genequine Biotherapeutics, Causeway Therapeutics, among others.

Degenerative Disc Disease Pipeline Market Drivers
• Increase in the prevalence of Degenerative Disc Disease, increasing Research and Development activities are some of the important factors that are fueling the Degenerative Disc Disease Market.

Degenerative Disc Disease Pipeline Market Barriers
• However, cost associated with the treatment, poor patient compliance and other factors are creating obstacles in the Degenerative Disc Disease Market growth.

Scope of Degenerative Disc Disease Pipeline Drug Insight
• Coverage: Global
• Key Degenerative Disc Disease Companies: Spine BioPharma, Inc., BioRestorative Therapies, Mesoblast, Ltd., Biosplice Therapeutics, Causeway Therapeutics, AnGes, Inc., DiscGenics, Kuros Biosciences, BioRestorative Therapies, Angitia Biopharmaceuticals, and others
• Key Degenerative Disc Disease Therapies: SB-01, BRTX-100, Rexlemestrocel-L, Lorecivivint, CWT 002, AMG0103, IDCT, KUR 113, BRTX-100, AGA111, and others
• Degenerative Disc Disease Therapeutic Assessment: Degenerative Disc Disease current marketed and Degenerative Disc Disease emerging therapies
• Degenerative Disc Disease Market Dynamics: Degenerative Disc Disease market drivers and Degenerative Disc Disease market barriers

Request for Sample PDF Report for Degenerative Disc Disease Pipeline Assessment and clinical trials - https://www.delveinsight.com/sample-request/degenerative-disc-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Contact Us:
Ankit Nigam
Manager Marketing
info@delveinsight.com
+14699457679

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.